- | Cerevance
Will We Ever Find a Cure for Dementia?
This precise approach “makes it possible to make drugs that only act on the cell type you care about,” reducing the unwanted side effects that most drugs have, says Margus, chief executive officer of Cerevance, a Boston-based drug development company focused on brain diseases. What’s more, it could lead to a major breakthrough in the field of dementia research. About 50 million people worldwide suffer from dementia, and still there is no treatment to stop or slow its progression.
- | NeuroRx
New emergency COVID-19 drug in testing phase excites South Florida doctors
Dr. Jonathan Javitt, the CEO of NeuroRx, said, “We’re talking to people who have critical COVID-19, with respiratory failure. That is people whose lungs have been affected by the COVID virus, such that their lungs don’t send oxygen properly to their bodies. Then the drug will be available at every hospital.”
- | Neubase Therapeutics
Winston-Salem woman raises awareness about Huntington’s disease
“It’s a chronic neurodegenerative process. Chronic just means it goes on very slowly over a long period of time,” said Friedlander, of NeuBase Therapeutics. Holder’s father is at the point in his diagnosis where he often forgets a pandemic is going on. Seeing people in masks scares him.
- | Redhill Biopharma
Yeliva see anything: Redhill calls out opaganib’s promise in COVID-19
Redhill Biopharma Ltd.’s chief operating officer, Gilead Raday, told BioWorld that the firm will build on positive results in severe COVID-19 patients with oral opaganib, a first-in-class sphingosine kinase-2 inhibitor that the company has branded Yeliva, and could seek emergency use authorization based on data due by year-end.
- | 9 Meters Biopharma
9 Meters Beats Corporate Competitors to Phase III Celiac Trials
9 Meters Biopharma’s program for celiac disease is among the most clinically advanced programs in development. With phase III trials underway and Fast Track designation from the FDA, “It’s, conservatively, at least one year ahead of everyone else’s,” John Temperato, president and CEO, told BioSpace.
- | Celyad
David Gilham on Single Vector Multiplexed shRNA Maintenance
David Edward Gilham of The University of Manchester discusses single vector multiplexed shRNA provides a non-gene edited strategy to concurrently knockdown the expression of multiple genes in CAR T cells presented at this year’s virtual ASCO.
- | Cue Biopharma
Mechanistic Action: Genesis Of A Biologics Pipeline?
It’s early days for Cue Biopharma’s CUE-101, the lead candidate in its IL-2-based CUE-100 Series. In pre-clinical studies, CUE-101 has demonstrated selective binding and preferential activation and expansion of antigen-specific T cells, dose-dependent effector cytokine production, and inhibition of tumor growth both as a monotherapy and in combination with a PD-1 inhibitor. Its first in-human clinical studies commenced last fall.
- | Heat Bio
No-one left behind: ensuring Covid-19 vaccines are effective in at-risk groups
Despite being most at risk from Covid-19, older people and those with compromised immune systems are unlikely to reap much benefit from Covid-19 vaccines, which are the main way we can overcome the viral pandemic. US-based Heat Biologics believes it has the answer to give extra protection to those with less robust immune systems.
